dexmedetomidine

Overview

Dexmedetomidine is a highly selective and potent α2-adrenergic receptor agonist widely used as a sedative, analgesic, and anxiolytic agent in both surgical and nonsurgical clinical settings. It exerts its primary effects by binding to α2-adrenergic receptors in the central and peripheral nervous system, producing dose-dependent sedation, analgesia, and sympatholysis without causing significant respiratory depression—a property that distinguishes it from many classical sedatives. Originally approved for intravenous use in intensive care and procedural sedation, dexmedetomidine has more recently been formulated in novel delivery formats including sublingual, nasal spray, and topical ophthalmic preparations, reflecting a broader expansion of its therapeutic applications. Its pharmacological profile also encompasses anti-inflammatory and neuroprotective properties, making it a subject of increasing interest beyond the perioperative setting.

Beyond sedation, dexmedetomidine has attracted significant attention for its neuroprotective effects in acute and chronic neurological conditions. Its ability to modulate neuroinflammation, support neuronal survival signaling, and interact with metabolic regulatory pathways such as AMPK/mTOR and sirtuin 1 (SIRT1) has positioned it as a candidate therapeutic agent in models of ischemic brain injury, neonatal hypoxic-ischemic encephalopathy, and neurodegenerative diseases including Alzheimer's disease (AD). These emerging mechanistic insights are driving a wave of preclinical and clinical research aimed at characterizing the full scope of dexmedetomidine's biological activity.

Focus of Latest Publications

Recent publications on dexmedetomidine have focused on its expanding therapeutic applications, with several studies examining perioperative and procedural uses as well as emerging neuroprotective and anticancer mechanisms. In clinical settings, dexmedetomidine has been investigated for prevention of postoperative delirium in elderly patients with lower limb fractures, with a trial protocol specifically addressing whether administration timing influences delirium risk. Another protocol is evaluating evening dexmedetomidine nasal spray for postoperative sleep disturbance after laparoscopic cholecystectomy, reflecting interest in noninvasive delivery for recovery-related complications. In ophthalmology, a prospective randomized trial assessed topical dexmedetomidine 0.008% for prevention of intraocular pressure elevation after Nd:YAG laser capsulotomy; it prevented acute IOP surges but was less effective than brimonidine, and no systemic or ocular side effects were reported.

Several recent preclinical studies have explored dexmedetomidine in neurological disease models. In adult zebrafish and rat models of Alzheimer's disease, dexmedetomidine was associated with reduced Beta amyloid accumulation, decreased amyloidogenic gene expression, attenuation of neuroinflammation, preservation of neuronal markers, and improvement in anxiety- and aggression-like behaviors. A preliminary rat study also suggested protective effects through activation of the AMPK/SIRT1 pathway, indicating a possible role in restoring energy homeostasis in metabolically driven Alzheimer's disease. In neonatal hypoxic-ischemic encephalopathy, dexmedetomidine reduced brain injury, neurological deficits, inflammation, and microglial M1 polarization in rats and BV2 cells, with Rbm47 identified as a mediator of its protective effects. Another study in ischemic brain injury examined cerebral protection via the brain-derived neurotrophic factor/TrkB pathway.

Dexmedetomidine has also been studied in procedural sedation and oncology-related contexts. In esophageal endoscopic submucosal dissection, investigators examined risk factors for adverse circulatory and respiratory events during dexmedetomidine-based sedation, underscoring safety concerns in older and comorbid patients. In esophageal carcinoma cells, dexmedetomidine potentiated cisplatin chemosensitivity by promoting pyroptosis through the SREBF1/miR-185-5p/CASP1 axis, reducing cell viability and lowering the cisplatin IC50. Additional reports include a case of severe hypotension after sublingual dexmedetomidine in an elderly patient, highlighting the need for safety monitoring outside clinical trials.

Method-development and delivery studies have also appeared, including a microneedle-based caramelized sucrose system designed for painless dexmedetomidine delivery, which showed rapid onset of sedation with minimal discomfort in clinical simulations. Collectively, these publications portray dexmedetomidine as a versatile agent under active investigation for sedation, perioperative complication prevention, neuroprotection, and chemosensitization, while also emphasizing the importance of dosing, timing, formulation, and safety.

Key Publications

• NEWJun Impact of dexmedetomidine administration timing on postoperative delirium in elderly patients with lower limb fractures: a study protocol for a randomised controlled trial. (BMJ open, 2026, PMID 42366003): "Although existing studies suggest that dexmedetomidine can reduce the risk of POD, the optimal timing of administration remains undetermined."
• NEWJun The protective effects of dexmedetomidine via AMPK/SIRT1 pathway activation in a rat model of alzheimer's disease: evidence from preliminary findings. (Molecular biology reports, 2026, PMID 42268445): "Dexmedetomidine (Dex), a selective α-2 adrenergic receptor agonist, has shown neuroprotective effects in acute neurological injury and energy homeostasis; however, its efficacy in metabolically driven AD models remains unclear."
• Jun The Prophylactic Effect of Dexmedetomidine 0.008% Versus Brimonidine 0.2% on IOP Elevation After Nd: YAG Laser Capsulotomy. (Pharmacology research & perspectives, 2026, PMID 42192576): "This prospective, double-masked, randomized clinical trial evaluated the efficacy of topical dexmedetomidine, a novel ophthalmic drop, in preventing IOP rise after Nd:YAG laser treatment."
• May Effect of evening dexmedetomidine nasal spray on postoperative sleep disturbance in patients undergoing laparoscopic cholecystectomy: protocol for a multicentre, prospective, randomised, double-blind, controlled trial. (BMJ open, 2026, PMID 42086269): "Dexmedetomidine, a highly selective α₂-adrenergic receptor agonist, offered in a nasal spray formulation with high bioavailability and convenient administration, may present a novel approach for PSD prevention."
• May Dexmedetomidine Exerts Multi-level Effects to Ameliorate Alzheimer's Disease Pathology in the Adult Zebrafish Brain. (Molecular neurobiology, 2026, PMID 42082800): "Dexmedetomidine (DEX), an α2-adrenergic receptor agonist with known neuroprotective properties, was investigated in an adult zebrafish model of AD..."
• May Dexmedetomidine Attenuates Neonatal Hypoxic-Ischemic Encephalopathy by Inhibiting Microglia Activation Through Upregulating Rbm47. (FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026, PMID 42065818): "The anesthetic dexmedetomidine (Dex) has been shown to reduce brain damage."
• Apr Risk Factors for Adverse Circulatory and Respiratory Events in Patients Undergoing Esophageal Endoscopic Submucosal Dissection Under Dexmedetomidine-Based Sedation. (The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2026, PMID 42026961): "...and dexmedetomidine (DEX) is being increasingly used."
• May Mechanisms of dexmedetomidine-induced cerebral protection following ischemic brain injury via the brain-derived neurotrophic factor-tyrosine kinase receptor B pathway. (Neuroreport, 2026, PMID 42015734): "To investigate the protective effects of dexmedetomidine on cerebral ischemia-reperfusion injury through the activation of the brain-derived neurotrophic factor (BDNF)/tyrosine kinase receptor B (TrkB) signaling pathway."
• Jun Dexmedetomidine potentiates cisplatin chemosensitivity in esophageal carcinoma cells via the SREBF1/miR-185-5p/Caspase-1 axis through pyroptosis. (International immunopharmacology, 2026, PMID 41966778): "This study aimed to elucidate the mechanism by which DEX enhances CDDP chemosensitivity in EC cells through pyroptosis."
• May Severe hypotension following sublingual dexmedetomidine administration in an elderly patient. (American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2026, PMID 41351540): "Sublingual dexmedetomidine is a recently introduced α2-adrenergic agonist approved for management of agitation in patients with schizophrenia or bipolar disorder."